Financial Data and Key Metrics Changes - Adjusted operating income grew by 21% and adjusted diluted EPS increased by 20% in Q3 2025 [6][16] - Consolidated revenue reached $80.7 billion, up 9%, with a gross profit of $2.9 billion, reflecting a 21% increase [17][18] - Consolidated operating income was $1.1 billion, also up 21% compared to the prior year [19] Business Line Data and Key Metrics Changes - U.S. Healthcare Solutions segment revenue was $72.9 billion, up 9%, with operating income increasing by 29% to $902 million [22][23] - International Healthcare Solutions segment revenue was $7.8 billion, up approximately 11%, but operating income decreased by 13% [24] Market Data and Key Metrics Changes - GLP-1 product sales increased by $1.4 billion or 19% year-over-year, although growth is moderating [22][38] - International segment revenue growth is expected to be 6% to 7% on an as-reported basis, up from a previous range of 3% to 4% [29] Company Strategy and Development Direction - The company is focused on enhancing patient care, strengthening specialty leadership, and leading with market leaders [7][11] - Investments in technology and capabilities are prioritized, including the acquisition of RCA and a pathway to full ownership in One Oncology [14][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. Healthcare Solutions segment's strong performance and the potential for sequential improvement in the International segment [41][42] - The company anticipates continued strong pharmaceutical utilization trends despite challenges in the international market [31][56] Other Important Information - The effective income tax rate was 20.7%, slightly down from 21% in the prior year [20] - The company ended the quarter with a cash balance of $2.2 billion and year-to-date adjusted free cash flow of approximately $100 million [21] Q&A Session Summary Question: Can you discuss the U.S. Healthcare segment's revenue growth moderation? - Management noted that revenue growth moderation was due to factors like biosimilars and a loss of a low-margin grocery customer, while operating income growth remained strong [36][38][40] Question: What is the outlook for the international business? - Management indicated that clinical trial activity has been subdued, impacting the international segment, but expects sequential growth in the global specialty logistics business [41][42] Question: How is the RCA acquisition tracking against expectations? - Management expressed satisfaction with the RCA acquisition, highlighting strong cultural fit and positive early customer feedback [46][47] Question: What are the potential impacts of the proposed hospital outpatient perspective rule? - Management acknowledged the potential competitive impacts but emphasized ongoing engagement with policymakers to maintain access for community providers [95] Question: What are the moving pieces for 2026 growth? - Management highlighted confidence in long-term guidance, with expectations for organic operating income growth of 5% to 8% and EPS growth of 8% to 12% [55][57] Question: How is the competitive environment in specialty distribution evolving? - Management stated that they remain focused on their strengths in specialty markets and continue to invest in capabilities to meet customer needs [81][83] Question: What is the impact of tariffs on the business? - Management reported no material impacts from tariffs but continues to monitor the situation closely [65][66][70]

Cencora (COR) came out with quarterly earnings of $4 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.34 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +5.82%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $4.08 per share when it actually produced earnings of $4.42, delivering a surprise of +8.33%. The sustainability of the st ...

Financial Performance - Q3 Fiscal 2025 - Revenue increased by 8.7% year-over-year to $80.7 billion[13] - Adjusted diluted EPS increased 19.8% year-over-year to $4.00[10, 12] - Consolidated adjusted operating income grew by 20.6% year-over-year[12] Segment Performance - Q3 Fiscal 2025 - U S Healthcare Solutions segment revenue increased by 8.5% to $72.9 billion, with operating income up 29.1% to $0.9 billion[15, 16] - International Healthcare Solutions segment revenue increased by 10.5% to $7.8 billion, but operating income decreased by 12.9% to $156.2 million[17, 18] - On a constant currency basis, International Healthcare Solutions revenue increased by 8.8% and operating income decreased by 16.2%[17, 18] Fiscal Year 2025 Guidance - Cencora updated its fiscal year 2025 adjusted diluted EPS guidance to a range of $15.85 to $16.00[10] - The company anticipates consolidated revenue growth of approximately 9%[20] - Adjusted operating income is projected to increase by 15% to 16%[20]

Exhibit 99.1 CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 CONSHOHOCKEN, PA, August 6, 2025 - Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis ...

Core Insights - Cencora (COR) is expected to report its third-quarter fiscal 2025 results on August 6, with a history of earnings surprises, averaging 6% over the last four quarters [1][2] Revenue and Earnings Estimates - The Zacks Consensus Estimate for Cencora's revenues is $80.33 billion, reflecting an 8.2% increase from the same quarter last year [2] - The consensus estimate for earnings is $3.78 per share, indicating a 13.2% improvement year-over-year [2] Segment Performance - The U.S. Healthcare Solutions segment is driving growth, with revenues of $68.3 billion in the second quarter, an 11% year-over-year increase, supported by strong demand for specialty medicines [3][4] - Specialty products are a key growth area, with operating income in the U.S. segment rising 23% in the fiscal second quarter, despite a 10% sequential decline in GLP-1 revenue due to seasonal factors [4][10] - The International Healthcare Solutions segment showed modest performance, generating $7.2 billion in revenue last quarter, with a 1% increase reported and a 17% decline in operating income [6][10] Strategic Developments - Cencora's acquisition of Retina Consultants of America (RCA) is expected to enhance the company's margin profile, with RCA's impact becoming more visible as integration progresses [7] - The company has raised its full-year operating income outlook for the U.S. Healthcare Solutions segment, anticipating continued benefits from strong first-half performance [3] Earnings Outlook - The model does not predict an earnings beat for Cencora this quarter, with an Earnings ESP of 0.00% [11]

Core Insights - Analysts forecast Cencora (COR) will report quarterly earnings of $3.78 per share, reflecting a year-over-year increase of 13.2% and revenues of $80.33 billion, an 8.2% increase compared to the previous year [1] Earnings Estimates - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3] Revenue Projections - Revenue from Total International Healthcare Solutions is projected to reach $7.30 billion, a 3.5% year-over-year increase [5] - Revenue from Total U.S. Healthcare Solutions is estimated at $72.81 billion, indicating an 8.4% increase from the prior-year quarter [5] - Revenue for International Healthcare Solutions- Alliance Healthcare is expected to be $5.77 billion, a 2.3% increase year-over-year [6] - Revenue from U.S. Healthcare Solutions- Animal Health is forecasted at $1.41 billion, reflecting a 3.1% year-over-year increase [6] - Revenue for U.S. Healthcare Solutions- Human Health is likely to reach $70.79 billion, suggesting a 7.6% year-over-year increase [7] - Revenue for International Healthcare Solutions- Other Healthcare Solutions is expected to be $1.51 billion, indicating a 7.1% increase from the previous year [7] Operating Income Estimates - The consensus estimate for Non-GAAP Operating Income from International Healthcare Solutions is $183.01 million, compared to $179.39 million from the previous year [8] - Non-GAAP Operating Income from U.S. Healthcare Solutions is forecasted to be $844.83 million, up from $698.31 million in the same quarter last year [8] Stock Performance - Cencora shares have decreased by 3.4% over the past month, contrasting with a 2.3% increase in the Zacks S&P 500 composite [8] - Cencora holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the overall market in the near future [8]

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise The market expects Cencora (COR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price ...

Investors with an interest in Medical stocks should continue to track McKesson and Cencora. These stocks will be looking to continue their solid performance. The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Another Medical stock, which ...

Core Insights - Citius Oncology has executed a distribution services agreement with Cencora to enhance its commercial infrastructure for the FDA-approved immunotherapy LYMPHIR [1][2][3] - The agreement aims to expand Citius Oncology's distribution network, ensuring product availability upon launch and supporting long-term scalability [2][3] - LYMPHIR is indicated for relapsed or refractory cutaneous T-cell lymphoma (CTCL) and is a targeted immune therapy that has shown antitumor activity [4][5] Company Overview - Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, focusing on developing and commercializing novel targeted oncology therapies [29][30] - The FDA approved LYMPHIR in August 2024, with an estimated initial market exceeding $400 million, indicating significant growth potential in an underserved market [29][30] - Citius Pharmaceuticals also has a late-stage pipeline that includes other critical care products, demonstrating a diverse portfolio [30] Product Details - LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that targets IL-2 receptors, leading to cell death in tumors expressing these receptors [4][5] - The product is indicated for adult patients with r/r Stage I-III CTCL after at least one prior systemic therapy [8][29] - The drug has received regulatory approval in Japan for CTCL and peripheral T-cell lymphoma (PTCL) prior to its FDA approval [5]

Group 1 - Cencora (COR) is a notable stock in the Medical sector, currently outperforming the sector with a year-to-date return of 29.6% compared to an average loss of 5.3% for the Medical group [4][5] - Cencora holds a Zacks Rank of 2 (Buy), indicating positive analyst sentiment and an improving earnings outlook, with a 2.9% increase in the consensus estimate for full-year earnings over the past 90 days [3] - The Medical group ranks 4 within the Zacks Sector Rank, which includes 16 different groups, highlighting the relative strength of this sector [2] Group 2 - Cencora is part of the Medical Services industry, which consists of 58 stocks and currently ranks 68 in the Zacks Industry Rank, with an average loss of 3.9% year-to-date [5] - Catalyst Pharmaceutical (CPRX), another stock in the Medical sector, has also outperformed the sector with a year-to-date return of 19.6% and holds a Zacks Rank of 2 (Buy) [4][6] - The Medical - Drugs industry, which includes Catalyst Pharmaceutical, ranks 55 and has experienced a decline of 1.8% so far this year [6]